List view / Grid view
The National Institute for Health and Care Excellence (NICE) has published final guidance recommending that five drugs to treat four different conditions should be routinely funded by the NHS.
28 September 2015 | By Victoria White
Praluent is the only EC-approved PCSK9 inhibitor that is available in two starting doses, offering two levels of efficacy...
17 September 2015 | By Victoria White
Under the terms of the acquisition agreement, Amgen will pay $300 million in cash at closing and up to $1.25 billion in additional payments...
21 July 2015 | By Victoria White
The EC has granted marketing authorisation for Repatha for the treatment of patients with uncontrolled cholesterol who require additional LDL-C reduction...
3 June 2015 | By Victoria White
Dezima Pharma has announced the publication of the phase 2b TULIP study results with its CETP inhibitor, TA-8995, in patients with mild dyslipidaemia...
22 May 2015 | By Victoria White
The CHMP has adopted a positive opinion for the marketing authorisation of Amgen’s Repatha for use in certain patients with high cholesterol...
20 May 2015 | By Victoria White
The global treatment market for dyslipidemia will more than double from $15.4 billion in 2013 to an estimated $37.9 billion by 2023, according to GlobalData...
Amgen (NASDAQ:AMGN) has announced new data from three separate analyses of Phase 2 and 3 studies evaluating evolocumab, a novel investigational low-density lipoprotein cholesterol (LDL-C)-lowering medication.
28 August 2014 | By Amgen
...in combination with statins in Japanese patients with high cardiovascular risk and high cholesterol.
29 July 2014 | By GlobalData
The launch of several drugs with “extraordinary blockbuster potential” will cause the acute coronary syndrome treatment market to more than triple in value...
28 January 2014 | By Amgen
Amgen announced that the Phase 3 LAPLACE-2 trial evaluating evolocumab in combination with statin therapy in patients with high cholesterol met its co-primary endpoints...
28 May 2013 | By AstraZeneca
AstraZeneca announced that it has entered into a definitive agreement to acquire Omthera Pharmaceuticals...
11 January 2013 | By Merck
Merck is taking steps to suspend the availability of TREDAPTIVE™ tablets worldwide...
22 July 2012 | By Eli Lilly and Company
Results from a pharmacokinetic study...
31 May 2012 | By Eli Lilly and Company
Results of the PREVAIL U.S. study...
